Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.82
- Piotroski Score 2.00
- Grade Buy
- Symbol (INZY)
- Company Inozyme Pharma, Inc.
- Price $2.68
- Changes Percentage (-3.94%)
- Change -$0.11
- Day Low $2.61
- Day High $2.80
- Year High $7.80
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $16.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.35
- Trailing P/E Ratio -3.43
- Forward P/E Ratio -3.43
- P/E Growth -3.43
- Net Income $-71,169,000
Income Statement
Quarterly
Annual
Latest News of INZY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Inozyme Pharma, Inc. (INZY) Stock Price, News, Quote & History
Inozyme Pharma specializes in developing treatments for rare diseases affecting vasculature, soft tissue, and skeleton. Their lead product, INZ-701, targets ENPP1 and ABCC6 deficiencies and end-stage ...
By Yahoo! Finance | 3 months ago -
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
A list of top biotech penny stocks includes Inozyme Pharma, Inc. (NASDAQ:INZY) showing promise in rare disease therapeutics. Analysts rate it a Strong Buy with potential for significant growth....
By Yahoo! Finance | 4 months ago
